Grant: Operating Grant: Antimicrobial Resistance - EOI
University of British Columbia
$10,000.00
Development of an immunologic tool for Clostridium difficile diagnosis and prognosis
EF 2016-17
Résumé
Clostridium difficile (C. diff) is one of the leading causes of hospital acquired infection. C. diff infection (CDI) causes colitis, leading to diarrhea, fever, and abdominal pain, which in severe cases can be fatal. CDI is one of the major public health priorities in Canada because of the suffering and tremendous health care costs associated with it. CDI develops when patients ingest the C. diff bacteria (from contaminated food or surfaces) and have abnormal "healthy" gut bacteria (typically, after taking antibiotics), which then allows the C. diff to grow and make two toxins, TcdA and TcdB, which damage the intestinal lining. One big challenge with CDI is figuring out which patients at risk will go on to get very sick with it, or relapse after they are first cured. Identifying the highest risk patients will help to determine who needs the most aggressive, expensive treatments to cure the initial infection and prevent relapses.
Despite its importance, very little is known about the immune response to the C. diff toxins. Some studies have found that antibodies to TcdA or TcdB protect people from getting sick, but others have not. Our lab has developed a new tool to study immune responses to C. diff, and in this project, we plan to use this test to study the natural immune response in patients with CDI and compare it to healthy controls and people receiving a new vaccine against C. diff. We hope to use this information to map out in detail the specific type of immune response that best protects people from CDI. Once we have this information, we can use it to develop rapid tests to measure these responses, which will help us identify the patients most at risk, and tailor the best prevention and treatment for them.
Programme
Operating Grant: Antimicrobial Resistance - EOI
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
349779
Name
Steiner Theodore S
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Development of an immunologic tool for Clostridium difficile diagnosis and prognosis
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Operating Grant: Antimicrobial Resistance - EOI
Keyworddelim
Clostridium Difficile; Iga And Igg; T Cells; Vaccines
Abstract
Clostridium difficile (C. diff) is one of the leading causes of hospital acquired infection. C. diff infection (CDI) causes colitis, leading to diarrhea, fever, and abdominal pain, which in severe cases can be fatal. CDI is one of the major public health priorities in Canada because of the suffering and tremendous health care costs associated with it. CDI develops when patients ingest the C. diff bacteria (from contaminated food or surfaces) and have abnormal "healthy" gut bacteria (typically, after taking antibiotics), which then allows the C. diff to grow and make two toxins, TcdA and TcdB, which damage the intestinal lining. One big challenge with CDI is figuring out which patients at risk will go on to get very sick with it, or relapse after they are first cured. Identifying the highest risk patients will help to determine who needs the most aggressive, expensive treatments to cure the initial infection and prevent relapses.
Despite its importance, very little is known about the immune response to the C. diff toxins. Some studies have found that antibodies to TcdA or TcdB protect people from getting sick, but others have not. Our lab has developed a new tool to study immune responses to C. diff, and in this project, we plan to use this test to study the natural immune response in patients with CDI and compare it to healthy controls and people receiving a new vaccine against C. diff. We hope to use this information to map out in detail the specific type of immune response that best protects people from CDI. Once we have this information, we can use it to develop rapid tests to measure these responses, which will help us identify the patients most at risk, and tailor the best prevention and treatment for them.
Competitiondate
201605
Approvedterm2
0 yr 8 mths
Pinamesdelim
Steiner, Theodore S
Approvedterm
0 an 8 mois
Cihrcontribution2
~ $10,000~ $0~